• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biopharmas that attract corporate venture investment more likely to be acquired, go public, analysis finds

Biopharmas that attract corporate venture investment more likely to be acquired, go public, analysis finds

May 30, 2012
CenterWatch Staff

Therapeutics companies that attract investment from corporate venture arms are more likely than other venture-backed companies to enter licensing deals, be acquired or complete an initial public offering, according to analysis from Burrill & Company, a diversified global financial services firm focused on the life sciences industry.

The analysis comes as the pharmaceutical industry, looking for new ways to access promising, early-stage technologies, have increasingly turned to making venture investments as a way to gain insight and access.

"Our analysis shows that companies that were able to attract the participation of a corporate venture fund had a significantly greater likelihood of providing an exit for its investors," said G. Steven Burrill, CEO of Burrill & Company. "The ability to attract corporate venture capital is a validation for companies that secure those investments."

The analysis, published in the June 2012 edition of The Burrill Report, examined all therapeutics venture investments made between January 1, 2000, and December 31, 2011, in the S&P Capital IQ database. A total of 2,907 companies received disclosed venture capital funding through 5,100 rounds of financing during that period. Of those companies, 9.9% (286 companies) received funding in part from a corporate venture fund.

Of the companies that received corporate venture funding during the period analyzed, 24.5% (70 companies) were acquired compared to 14.4% (380 companies) for those that did not receive funding from a corporate venture investor. But while having corporate venture funding was a greater predictor of an eventual acquisition, it wasn't because the parent of the corporate venture fund was likely to buy the company. In fact, only 8.6%, or six of the corporate venture funded companies that were eventually acquired, were acquired by the parent of that corporate venture arm.

Companies that received corporate venture funding were also far more likely to enter into licensing or collaboration agreements. A total of 48.4%, or 139 companies, that received corporate venture funding during the period entered into at least one licensing/collaboration agreement, compared to 29.9% of non-corporate venture funded companies (782 companies) that entered into licensing/collaboration agreements during the period.

"Though it's unclear from the research, that may reflect that having corporate venture funding helps guide companies to work on projects that are of higher interest to potential acquirers," said Burrill.

Corporate venture funding was also a greater predictor of an eventual IPO for a company. A total of 12.2% of corporate venture backed companies (35 companies) successfully completed IPOs, compared to 7.8%, or 205 companies, in the analysis that did not receive corporate venture backing.

There was not a significant difference between the two groups in terms of the time from first venture funding to an M&A or IPO for the companies in the analysis that achieved exits. The companies backed with corporate venture capital achieved exits, on average, at four years, compared to four years and three months for non-corporate venture backed companies.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing